Discoverer and developer of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer.
Principia is a privately held biopharmaceutical company focused on the design and development of reversible covalent small molecule drugs. The company is the dominant developer of reversible covalent therapeutics. Principia is creating a pipeline of differentiated drug candidates that offer superior safety and efficacy compared with other technologies. The company is leveraging its reversible covalent platform to build a pipeline of internal drug candidates and to establish partnerships with leading biopharmaceutical companies. Principia's platform is also being used to develop unique research tools to explore new biology, validate new disease targets, and serve as the source of its future pipeline.